Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry R Büller

Showing results (1-10 of 278) with videos related to

Pageof 28
Sort By:
The New England Journal of Medicine|January 3, 2014
Edoxaban versus warfarin for venous thromboembolismHarry R Büller
Seminars in Thrombosis and Hemostasis|January 20, 2004
Factor Xa is a superior target to factor IIa for antithrombotic therapiesHarry R Büller
Seminars in Thrombosis and Hemostasis|June 20, 2002
Treatment of symptomatic venous thromboembolism: improving outcomesHarry R Büller
Journal of Clinical Epidemiology|September 5, 2003
When do we need what evidence?Martin H Prins, Harry R Büller
The British Journal of Surgery|March 2, 2005
New anticoagulants and thromboprophylaxisMarnix R Hoppener, Harry R Büller
The New England Journal of Medicine|August 15, 2003
Secondary prophylaxis with warfarin for venous thromboembolismHarry R Büller, Martin H Prins
Hematology. American Society of Hematology. Education Program|December 6, 2015
Using direct oral anticoagulants (DOACs) in cancer and other high-risk populationsNick van Es, Harry R Büller
Nature Clinical Practice. Cardiovascular Medicine|November 24, 2006
Could D-dimer provide a definitive diagnosis in patients with suspected pulmonary embolism?Nadine S Gibson, Harry R Büller
Seminars in Thrombosis and Hemostasis|June 20, 2002
Benefit of selective factor inhibitionAlexander G G Turpie, Harry R Büller
Hematology/Oncology Clinics of North America|July 28, 2010
Heparin and survival in cancer patientsFrederiek F van Doormaal, Harry R Büller
Pageof 28

Showing results (1-10 of 278) with videos related to

Sort By:
Pageof 28
The New England Journal of Medicine|January 3, 2014
Edoxaban versus warfarin for venous thromboembolismHarry R Büller
Seminars in Thrombosis and Hemostasis|January 20, 2004
Factor Xa is a superior target to factor IIa for antithrombotic therapiesHarry R Büller
Seminars in Thrombosis and Hemostasis|June 20, 2002
Treatment of symptomatic venous thromboembolism: improving outcomesHarry R Büller
Journal of Clinical Epidemiology|September 5, 2003
When do we need what evidence?Martin H Prins, Harry R Büller
The British Journal of Surgery|March 2, 2005
New anticoagulants and thromboprophylaxisMarnix R Hoppener, Harry R Büller
The New England Journal of Medicine|August 15, 2003
Secondary prophylaxis with warfarin for venous thromboembolismHarry R Büller, Martin H Prins
Hematology. American Society of Hematology. Education Program|December 6, 2015
Using direct oral anticoagulants (DOACs) in cancer and other high-risk populationsNick van Es, Harry R Büller
Nature Clinical Practice. Cardiovascular Medicine|November 24, 2006
Could D-dimer provide a definitive diagnosis in patients with suspected pulmonary embolism?Nadine S Gibson, Harry R Büller
Seminars in Thrombosis and Hemostasis|June 20, 2002
Benefit of selective factor inhibitionAlexander G G Turpie, Harry R Büller
Hematology/Oncology Clinics of North America|July 28, 2010
Heparin and survival in cancer patientsFrederiek F van Doormaal, Harry R Büller
Pageof 28